“Diosgenin Ameliorates Non-Alcoholic Fatty Liver Disease in Rats by Modulating Signaling Pathway”

https://pubmed.ncbi.nlm.nih.gov/38114120

Diosgenin alleviates non-alcoholic fatty liver disease in rats by modulating the mTOR/SREBP-1c/HSP60/MCAD/SCAD signaling pathway to reduce lipid synthesis and improve mitochondrial function.